Praxis Precision Medicines, Inc. PRAX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s retained earnings?
- Praxis Precision Medicines, Inc. (PRAX) reported retained earnings of -$1.23B in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s retained earnings changed year-over-year?
- Praxis Precision Medicines, Inc.'s retained earnings decreased by 36.0% year-over-year, from -$906.04M to -$1.23B.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s retained earnings has grown at a 50.1% compound annual growth rate (CAGR), from -$149.55M to -$1.14B.
- What does retained earnings mean?
- The cumulative profit or loss the company has generated over time.
- How do you interpret retained earnings?
- Negative values are expected for pre-revenue biotech firms; a trend toward zero or positive indicates progress toward profitability.
- How does retained earnings compare across companies?
- Consistently negative for early-stage clinical companies until a product reaches commercial success.